[Critical study of current tumoral markers].
A number of biological markers have been recently introduced in clinical use as an aid for diagnosis and monitoring of malignant tumors. Some of them are relatively tumor-specific, i.e. CA 125 for non-mucinous ovarian cancer, CA 15.3 for breast cancer, PSA for prostate cancer, CA 19.9 for colo-rectal and pancreatic cancers. The clinical usefulness, the sensitivity and specificity of these tumor markers and of a few others (CA 50, SCC and TPA) are commented in this review.
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology; D006063:Chorionic Gonadotropin / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D010455:Peptides / Q000032:analysis; D010928:Placental Lactogen / Q000032:analysis; D017430:Prostate-Specific Antigen; D019396:Tissue Polypeptide Antigen
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D010455:Peptides; D019396:Tissue Polypeptide Antigen; C036649:tumor antigen TA-4, human; D010928:Placental Lactogen; D017430:Prostate-Specific Antigen
Etude critique des marqueurs tumoraux récents.